Last reviewed · How we verify
Ketamine Infustion
Ketamine Infustion is a Small molecule drug developed by Mayo Clinic. It is currently FDA-approved. Also known as: Ketamine.
Ketamine Infusion, marketed by Mayo Clinic, is a therapeutic option in the psychiatric and pain management sectors without a specified primary indication. A key strength is the protection of its composition through a patent expiring in 2028, providing a period of market exclusivity. The primary risk lies in the unspecified revenue and lack of detailed clinical trial results, which may affect market confidence and competitive positioning.
At a glance
| Generic name | Ketamine Infustion |
|---|---|
| Also known as | Ketamine |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine Infustion CI brief — competitive landscape report
- Ketamine Infustion updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about Ketamine Infustion
What is Ketamine Infustion?
Who makes Ketamine Infustion?
Is Ketamine Infustion also known as anything else?
What development phase is Ketamine Infustion in?
Related
- Manufacturer: Mayo Clinic — full pipeline
- Also known as: Ketamine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing